-
1 Comment
Analytica Limited is currently in a long term downtrend where the price is trading 16.8% below its 200 day moving average.
From a valuation standpoint, the stock is 260.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 928.9.
Analytica Limited's total revenue rose by 7.2% to $781K since the same quarter in the previous year.
Its net income has dropped by 10.7% to $-450K since the same quarter in the previous year.
Finally, its free cash flow grew by 44.5% to $-190K since the same quarter in the previous year.
Based on the above factors, Analytica Limited gets an overall score of 2/5.
| ISIN | AU000000ALT0 |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | AU |
| CurrencyCode | AUD |
| Beta | 1.15 |
|---|---|
| Dividend Yield | 0.0% |
| Market Cap | 5M |
| PE Ratio | None |
| Target Price | None |
Analytica Limited designs, develops, and supplies medical devices in Australia, China, and the Middle East. The company's lead product includes PeriCoach system, an e-health treatment system for women used in treatment of stress urinary incontinence. Its PeriCoach comprises a device, Web portal, and smartphone app for evaluating activity in pelvic floor muscles. The company also provides Autostart Burette Infusion System for monitoring and refilling of burettes in intravenous fluid infusion. Analytica Limited was incorporated in 1985 and is based in Brisbane, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALT.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
